Stifel Updates Ests on Biogen (BIIB) Following Q1 Report; Affirms at 'Hold'

Go back to Stifel Updates Ests on Biogen (BIIB) Following Q1 Report; Affirms at 'Hold'

Biogen (BIIB) Tops Q1 EPS by 33c

April 21, 2016 7:16 AM EDT

Biogen (NASDAQ: BIIB) reported Q1 EPS of $4.79, $0.33 better than the analyst estimate of $4.46. Revenue for the quarter came in at $2.73 billion versus the consensus estimate of $2.75 billion.

Growth was driven by a 15% increase in worldwide TECFIDERA revenues as well as... More